Clinicohematologic characteristics and levels ofFLT3/ITD in paired diagnostic and first relapse samples in adult AML patients with single mutations
| Patient . | Age/sex . | FAB subtype . | Chromosome/genetic abnormality . | Length of FLT3/ITD (bp) . | % leukemic blasts in BM . | FLT3/ITD level (%) . | %FLT3/ITD expression by RT-PCR . | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Diagnosis . | Relapse . | Diagnosis . | Relapse . | Diagnosis . | Relapse . | |||||
| 1 | 38/F | M5a | 46,XX | 69 | 95.3 | 97.3 | 39.2 | 100 | 31.4 | 93.8 |
| 2 | 66/F | M2 | 46,XX | 33 | 51.6 | 94.0 | 15.8 | 22.2 | 20.5 | 38.4 |
| 3 | 56/F | M2 | 46,XX | 60 | 69.4 | 73.0 | 39.1 | 64.6 | 38.6 | 97.1 |
| 4 | 50/M | M2 | 46,XY | 33 | 49.0 | 36.2 | 10.5 | 50.8 | NA | 96.9 |
| 5 | 29/F | M2 | ND | 36 | 66.2 | 56.4 | 29.8 | 39.8 | NA | 93.2 |
| 6 | 67/M | M4 | 46,XY | 33 | 83.6 | 46.0 | 32.8 | 60.7 | 33.1 | NA |
| 7 | 21/M | M0 | ND | 30 | 94.3 | 88.8 | 56.5 | 58.2 | 57.3 | 57.4 |
| 8 | 32/M | M2 | 46,XY | 15 | 51.6 | 52.2 | 44.5 | 37.9 | 34.4 | 45.4 |
| 9 | 34/M | M5a | 46,XY | 45 | 96.2 | 51.1 | 33.1 | 10.2 | 36.8 | 80.0 |
| 10 | 61/F | M3 | 46,XX,t(15;17)(q22;q21) | 30 | 90.2 | 84.4 | 9.8 | 0 | 8.1 | 0 |
| 11 | 45/M | M3 | 46,XY,add(6)(p22),t(15;17) (q22;q21) | 21 | 84.1 | 59.0 | 0 | 50.2 | 0 | 41.7 |
| 12 | 47/F | M2 | 46,XX | 165 | 42.6 | 90.8 | 0 | 16.5 | 0 | 40.5 |
| 13 | 60/M | M2 | ND | 63 | 77.0 | 64.8 | 0 | 42.1 | 0 | 19.4 |
| 14 | 60/M | M2 | ND | 24 | 73.6 | 98.7 | 0 | 88.6 | 0 | 100.0 |
| 15 | 41/F | M1 | 46,XX | 63 | 92.8 | 73.0 | 0 | 31.7 | 0 | 46.8 |
| 16 | 36/F | M2 | 46,XX | 24 | 92.5 | 39.2 | 0 | 35.5 | 0 | 70.9 |
| 17 | 48/F | M2 | 46,XX, partial tandem duplication ofMLL | 63 | 65.8 | 42.8 | 0 | 1.0 | 0 | 1.5 |
| Patient . | Age/sex . | FAB subtype . | Chromosome/genetic abnormality . | Length of FLT3/ITD (bp) . | % leukemic blasts in BM . | FLT3/ITD level (%) . | %FLT3/ITD expression by RT-PCR . | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Diagnosis . | Relapse . | Diagnosis . | Relapse . | Diagnosis . | Relapse . | |||||
| 1 | 38/F | M5a | 46,XX | 69 | 95.3 | 97.3 | 39.2 | 100 | 31.4 | 93.8 |
| 2 | 66/F | M2 | 46,XX | 33 | 51.6 | 94.0 | 15.8 | 22.2 | 20.5 | 38.4 |
| 3 | 56/F | M2 | 46,XX | 60 | 69.4 | 73.0 | 39.1 | 64.6 | 38.6 | 97.1 |
| 4 | 50/M | M2 | 46,XY | 33 | 49.0 | 36.2 | 10.5 | 50.8 | NA | 96.9 |
| 5 | 29/F | M2 | ND | 36 | 66.2 | 56.4 | 29.8 | 39.8 | NA | 93.2 |
| 6 | 67/M | M4 | 46,XY | 33 | 83.6 | 46.0 | 32.8 | 60.7 | 33.1 | NA |
| 7 | 21/M | M0 | ND | 30 | 94.3 | 88.8 | 56.5 | 58.2 | 57.3 | 57.4 |
| 8 | 32/M | M2 | 46,XY | 15 | 51.6 | 52.2 | 44.5 | 37.9 | 34.4 | 45.4 |
| 9 | 34/M | M5a | 46,XY | 45 | 96.2 | 51.1 | 33.1 | 10.2 | 36.8 | 80.0 |
| 10 | 61/F | M3 | 46,XX,t(15;17)(q22;q21) | 30 | 90.2 | 84.4 | 9.8 | 0 | 8.1 | 0 |
| 11 | 45/M | M3 | 46,XY,add(6)(p22),t(15;17) (q22;q21) | 21 | 84.1 | 59.0 | 0 | 50.2 | 0 | 41.7 |
| 12 | 47/F | M2 | 46,XX | 165 | 42.6 | 90.8 | 0 | 16.5 | 0 | 40.5 |
| 13 | 60/M | M2 | ND | 63 | 77.0 | 64.8 | 0 | 42.1 | 0 | 19.4 |
| 14 | 60/M | M2 | ND | 24 | 73.6 | 98.7 | 0 | 88.6 | 0 | 100.0 |
| 15 | 41/F | M1 | 46,XX | 63 | 92.8 | 73.0 | 0 | 31.7 | 0 | 46.8 |
| 16 | 36/F | M2 | 46,XX | 24 | 92.5 | 39.2 | 0 | 35.5 | 0 | 70.9 |
| 17 | 48/F | M2 | 46,XX, partial tandem duplication ofMLL | 63 | 65.8 | 42.8 | 0 | 1.0 | 0 | 1.5 |
ND indicates not done; NA, not available.